托特罗定对回肠原位新膀胱术后夜间尿失禁的短期效果:一项随机交叉安慰剂对照研究
这项前瞻性随机交叉安慰剂对照研究评估托特罗定治疗回肠原位新膀胱(ONB)术后夜间尿失禁(NUI)的效果。患者随机分入托特罗定组(T组,睡前4 mg缓释托特罗定)和安慰剂组(P组),治疗4周后洗脱2周再交叉治疗4周。T组在兩個阶段的主要指标(ICIQ-SF评分和每晚尿垫数)均显著优于P组,口干发生率为20.8%。作者认为托特罗定似乎是治疗根治性膀胱切除及ONB术后NUI的良好选择,但需进一步研究长期效果及相关尿动力学特征。
要点
- 托特罗定组两个阶段的ICIQ-SF评分和每晚尿垫数均较安慰剂组显著下降(P<0.001)。
- 首次分配后托特罗定组60例(77.9%)报告改善,安慰剂组4例(5.5%),P<0.001。
- 交叉后托特罗定组46例(73%)、安慰剂组7例(11.9%)报告改善,P<0.001。
核心结论
- 托特罗定似乎是治疗根治性膀胱切除及回肠原位新膀胱术后夜间尿失禁的良好选择,但需进一步研究明确长期效果及相关尿动力学特征。
研究设计与样本
- 前瞻性随机交叉安慰剂对照研究(clinicaltrials.gov: NCT02877901),纳入回肠原位新膀胱术后夜间尿失禁患者,随机等分为T组和P组。
- T组睡前接受4 mg缓释托特罗定,P组接受安慰剂,治疗4周后洗脱2周,再交叉至另一治疗方案治疗4周。
- 172例患者中,两个阶段分别有150例和122例完成评估;采用每晚尿垫数(PPN)和阿拉伯语版国际尿失禁咨询问卷简表(ICIQ-SF)评估。
主要发现
- 两个研究阶段中,T组平均ICIQ-SF评分和PPN均较P组显著下降(P<0.001)。
- T组首次分配后15例(10%)、交叉后11例(9%)患者达到干爽。
- 首次分配后T组60例(77.9%)报告改善,P组4例(5.5%),P<0.001;交叉后T组46例(73%)、P组7例(11.9%)报告改善,P<0.001。
- 口干发生于31例(20.8%)患者。
临床怎么用
- 作者认为托特罗定似乎是治疗根治性膀胱切除及回肠原位新膀胱术后夜间尿失禁的良好选择。
- 作者指出需进一步研究明确长期效果及相关尿动力学特征。
局限性
- 原文结论指出需进一步研究以明确长期效果及相关尿动力学特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the effect of tolterodine in the treatment of nocturnal urinary incontinence (NUI) after ileal orthotopic neobladder (ONB). PATIENTS AND METHODS: This is a prospective randomised placebo-controlled crossover study (clinicaltrials.gov: NCT02877901). Patients with NUI after ONB were randomly allocated into two equal groups. Group T received 4 mg extended-release tolterodine at bed-time and Group P received placebo for 4 weeks followed by 2 weeks of washout, then crossed over to the alternate therapy for 4 weeks. Patients were assessed by the number of pads used per night (PPN) and with the Arabic version of the International Consultation on Incontinence Modular Questionnaire-Short Form (ICIQ-SF) at both phases of the study. The outcomes were the rate of NUI improvement and medication adverse events. RESULTS: Out of 172 patients, 150 and 122 patients were evaluated at both phases of the study. The mean ICIQ-SF scores and PPN were significantly decreased in Group T compared to Group P in both study phases (P < 0.001). In Group T, 15 (10%) and 11 (9%) patients became dry after the first allocation and crossover, respectively. In Group T, 60 (77.9%) patients reported improvement vs four (5.5%) in Group P (P < 0.001) after the first allocation. Similarly, 46 (73%) and seven (11.9%) patients showed improvement in groups T and P after the crossover, respectively (P < 0.001). Dry mouth occurred in 31 (20.8%) patients. CONCLUSIONS: Tolterodine seems to be a good choice for treatment of NUI after radical cystectomy and ONB. However, further studies are needed to delineate the long-term effects and the associated urodynamic characteristics.
引用
- Zahran MH, Harraz AM, Taha DE, et al. The short-term effects of tolterodine on nocturnal incontinence after ileal orthotopic neobladder: a randomised crossover placebo-controlled study. BJU Int. 2019. PMID: 30946525. doi:10.1111/bju.14769
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。